Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
DBM
MCID: LKM056
MIFTS: 47

Leukemia, Chronic Lymphocytic 2 (DBM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia, Chronic Lymphocytic 2

About this section

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic 2:

Name: Leukemia, Chronic Lymphocytic 2 57 29
Leukemia, Chronic Lymphocytic, Susceptibility to, 2 57 13
B-Cell Malignancy, Low-Grade 57 70
Leukemia, Chronic Lymphocytic, B-Cell; Bcll 57
Leukemia, Chronic Lymphocytic, B-Cell 57
Disrupted in B-Cell Malignancy; Dbm 57
Lymphocytic Leukemia Chronic B-Cell 54
Disrupted in B-Cell Malignancy 57
Chronic Lymphocytic Leukemia 70
Clls2 57
Bcll 57
Dbm 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant (13q14)


HPO:

31
leukemia, chronic lymphocytic 2:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

OMIM® 57 109543
ICD10 32 C91.1
MedGen 41 C1868683
UMLS 70 C0023434 C1868683
Sources

Summaries for Leukemia, Chronic Lymphocytic 2

About this section
MalaCards based summary : Leukemia, Chronic Lymphocytic 2, also known as leukemia, chronic lymphocytic, susceptibility to, 2, is related to immune deficiency disease and leukemia, chronic lymphocytic, and has symptoms including fatigue, angina pectoris and chest pain. An important gene associated with Leukemia, Chronic Lymphocytic 2 is CLLS2 (Disrupted In B-Cell Neoplasia), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Interleukin-4 and 13 signaling. The drugs Valganciclovir and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and myeloid, and related phenotypes are chronic lymphatic leukemia and hematopoietic system

More information from OMIM: 109543
Sources

Related Diseases for Leukemia, Chronic Lymphocytic 2

About this section

Diseases in the Leukemia, Chronic Lymphocytic family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 3 Leukemia, Chronic Lymphocytic 4
Leukemia, Chronic Lymphocytic 5 Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 immune deficiency disease 29.2 ZAP70 CD5 CD38 ATM
2 leukemia, chronic lymphocytic 26.6 ZAP70 MS4A1 MCL1 IGHM FCER2 CLLS2
3 periodontitis, chronic 10.1
4 periodontitis 10.1
5 cryoglobulinemia, familial mixed 10.1 IGHM CD5
6 chromosomal triplication 10.1 ZAP70 BCL3
7 gallbladder lymphoma 10.1 FCER2 CD5
8 endocrine exophthalmos 10.1 CD5 ATM
9 osteonecrosis 10.1
10 gingival recession 10.1
11 spherocytosis, type 5 10.1 MCL1 CD38
12 lymphoplasmacytic lymphoma 10.1 CD5 CD38
13 anemia, autoimmune hemolytic 10.0 ZAP70 CD5
14 plasma protein metabolism disease 10.0 CD5 CD38
15 bone resorption disease 10.0
16 spinal stenosis 10.0
17 back pain 10.0
18 plasmablastic lymphoma 10.0 MS4A1 CD38
19 cold agglutinin disease 10.0 MS4A1 IGHM
20 leukocyte disease 10.0 MCL1 CD5 CD38
21 rhabdomyosarcoma 9.9
22 b-cell non-hodgkin lymphoma 9.9 MS4A1 ATM
23 intravascular large b-cell lymphoma 9.9 CD5 BCL2
24 extramedullary plasmacytoma 9.9 CD38 BCL2
25 papillomatosis, confluent and reticulated 9.8
26 retinoblastoma 9.8
27 type 1 diabetes mellitus 9.8
28 suppression of tumorigenicity 12 9.8
29 leukemia, chronic myeloid 9.8
30 human immunodeficiency virus type 1 9.8
31 scoliosis 9.8
32 gestational diabetes 9.8
33 hyperinsulinism 9.8
34 skin carcinoma 9.8
35 hyperglycemia 9.8
36 adenoma 9.8
37 myeloid leukemia 9.8
38 47,xyy 9.8
39 dentinogenesis imperfecta type 2 9.8
40 t-cell prolymphocytic leukemia 9.8 MS4A1 ATM
41 peripheral t-cell lymphoma 9.8 MS4A1 CD5 CD38
42 primary central nervous system lymphoma 9.8 IGHM BCL2
43 chromosome 13q14 deletion syndrome 9.8 ZAP70 CD5 CD38 ATM
44 cll/sll 9.8 ZAP70 CD5 CD38 ATM
45 richter's syndrome 9.8 ZAP70 CD5 CD38 ATM
46 lymphoma, mucosa-associated lymphoid type 9.7 ZAP70 CD5 BCL2
47 inflammatory myofibroblastic tumor 9.7 MCL1 FCER2 BCL2
48 myeloma, multiple 9.7 MCL1 CD5 CD38 ATM
49 common variable immunodeficiency 9.6 ZAP70 MS4A1 CD38
50 prolymphocytic leukemia 9.6 ZAP70 FCER2 CD5 CD38 ATM

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic 2:



Diseases related to Leukemia, Chronic Lymphocytic 2
Sources

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic 2

About this section

Human phenotypes related to Leukemia, Chronic Lymphocytic 2:

31
# Description HPO Frequency HPO Source Accession
1 chronic lymphatic leukemia 31 HP:0005550

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Oncology:
b-cell chronic lymphocytic leukemia (cll)

Clinical features from OMIM®:

109543 (Updated 05-Apr-2021)

UMLS symptoms related to Leukemia, Chronic Lymphocytic 2:


fatigue; angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Leukemia, Chronic Lymphocytic 2:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.61 ATM BCL2 BCL3 CD38 CD5 FCER2
2 immune system MP:0005387 9.28 ATM BCL2 BCL3 CD38 CD5 FCER2
Sources

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic 2

About this section

Drugs for Leukemia, Chronic Lymphocytic 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 286)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
2
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
3
Chlorambucil Approved Phase 4 305-03-3 2708
4 Alkylating Agents Phase 4
5 Immunosuppressive Agents Phase 4
6 Epoetin alfa Phase 4 113427-24-0
7 Hematinics Phase 4
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
10
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
11
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
12
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
13
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
14
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
15
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
16
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
17
Venetoclax Approved, Investigational Phase 3 1257044-40-8 49846579
18
Fexofenadine Approved, Investigational Phase 3 83799-24-0 3348
19
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
20
Ocrelizumab Approved, Investigational Phase 3 637334-45-3
21
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
22
ofatumumab Approved Phase 3 679818-59-8 6918251
23
Lenograstim Approved, Investigational Phase 3 135968-09-1
24
Tenofovir Experimental, Investigational Phase 3 147127-20-6 464205
25 Anti-Inflammatory Agents Phase 3
26 Antineoplastic Agents, Hormonal Phase 3
27 Tubulin Modulators Phase 3
28 Antimitotic Agents Phase 3
29
Liposomal doxorubicin Phase 3 31703
30 Mitogens Phase 3
31 Antiviral Agents Phase 3
32 Reverse Transcriptase Inhibitors Phase 3
33 Anti-Retroviral Agents Phase 3
34 Anti-HIV Agents Phase 3
35 Hormones Phase 3
36 Gastrointestinal Agents Phase 3
37 Antiemetics Phase 3
38 Neuroprotective Agents Phase 3
39 Hormone Antagonists Phase 3
40 glucocorticoids Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Histamine H1 Antagonists, Non-Sedating Phase 3
43 Myeloma Proteins Phase 3
44 Histamine H1 Antagonists Phase 3
45 Paraproteins Phase 3
46 Histamine Antagonists Phase 3
47 Anti-Allergic Agents Phase 3
48 Immunologic Factors Phase 3
49 Antibodies, Monoclonal Phase 3
50 Antineoplastic Agents, Immunological Phase 3

Interventional clinical trials:

(show top 50) (show all 854)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
3 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
4 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
5 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
6 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
7 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
8 Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens Not yet recruiting NCT04790045 Phase 4 Venetoclax
9 Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
10 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
11 Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
12 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
13 Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
14 Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
15 Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
16 A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity Completed NCT03730129 Phase 2, Phase 3 Hizentra
17 Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
18 Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
19 International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia Completed NCT01118234 Phase 3 Rituximab
20 Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
21 A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
22 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
23 A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia Completed NCT01905943 Phase 3 Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
24 A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Completed NCT02301156 Phase 3 Ublituximab;ibrutinib
25 Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL) Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
26 Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity Completed NCT00281892 Phase 3 Fludarabine mono
27 A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia Completed NCT01892618 Phase 3 Prevenar 13;Pneumovax
28 A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT02264574 Phase 3 Ibrutinib;Obinutuzumab;Chlorambucil
29 A Pilot Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) Completed NCT02801578 Phase 2, Phase 3 Ibrutinib
30 Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
31 A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00086580 Phase 3
32 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial) Completed NCT00774345 Phase 3 Lenalidomide;Placebo
33 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
34 Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
35 Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
36 Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01722487 Phase 3 Ibrutinib;Chlorambucil
37 A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects With Refractory Chronic Lymphocytic Leukemia Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab
38 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01569295 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo to match idelalisib
39 A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
40 A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
41 Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
42 A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
43 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib
44 A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 Completed NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
45 Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide Completed NCT00004218 Phase 3 chlorambucil;cyclophosphamide;doxorubicin hydrochloride;fludarabine phosphate;prednisolone;vincristine sulfate
46 Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate
47 An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed NCT01500083 Phase 3 Bendamustine at a dose of 100 mg/m2;Bendamustine at a dose of 120 mg/m2
48 Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00003764 Phase 3 cyclophosphamide;fludarabine phosphate
49 Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT00564512 Phase 3 cyclophosphamide;fludarabine
50 Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO Completed NCT00645606 Phase 3

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic 2

Inferred drug relations via UMLS 70 / NDF-RT 51 :


alemtuzumab
Chlorambucil
Cladribine
Cyclophosphamide
etoposide phosphate
fludarabine
Fludarabine phosphate
Ibrutinib
Ifosfamide
Immunoglobulins, Intravenous
mercaptopurine
pegaspargase
Uracil Mustard
Sources

Genetic Tests for Leukemia, Chronic Lymphocytic 2

About this section

Genetic tests related to Leukemia, Chronic Lymphocytic 2:

# Genetic test Affiliating Genes
1 Leukemia, Chronic Lymphocytic 2 29
Sources

Anatomical Context for Leukemia, Chronic Lymphocytic 2

About this section

MalaCards organs/tissues related to Leukemia, Chronic Lymphocytic 2:

40
T Cells, B Cells, Myeloid, Bone, Bone Marrow, Liver, Lymph Node
Sources

Publications for Leukemia, Chronic Lymphocytic 2

About this section

Articles related to Leukemia, Chronic Lymphocytic 2:

(show top 50) (show all 321)
# Title Authors PMID Year
1
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. 57
21205967 2011
2
Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. 57
9205107 1997
3
Evidence for a new tumour suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. 57
8490658 1993
4
Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia. 54 61
7576105 1995
5
ZAP70: a master regulator of adaptive immunity. 54
20135127 2010
6
IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. 54
20060740 2010
7
Adipose tissue depots of Holstein cows are immune responsive: inflammatory gene expression in vitro. 54
19914024 2010
8
The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia. 54
20156175 2010
9
Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy. 54
20181625 2010
10
IL-21 and T follicular helper cells. 54
19933709 2010
11
VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. 54
19965686 2010
12
Genetic and immunophenotypic profile of IGH@ rearrangement detected by fluorescence in situ hybridization in 149 cases of B-cell chronic lymphocytic leukemia. 54
19963136 2010
13
Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia. 54
19847197 2010
14
Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia. 54
19487028 2009
15
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. 54
19751240 2009
16
Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis. 54
19723537 2009
17
BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. 54
19395025 2009
18
Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. 54
19595676 2009
19
Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. 54
19789217 2009
20
The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. 54
19581935 2009
21
Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. 54
19459926 2009
22
Naringin Protects against Rotenone-induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells. 54
19885011 2009
23
Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation. 54
19296913 2009
24
Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. 54
18241213 2009
25
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. 54
19092849 2009
26
HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? 54
19298722 2009
27
ZAP-70 and Syk expression in canine lymphoid cells and preliminary results on leukaemia cases. 54
19144411 2009
28
[Immunohistochemical detection of ZAP-70 protein and its importance in the diagnostics of B-CLL]. 54
19534392 2009
29
CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians. 54
19240243 2009
30
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. 54
19074730 2009
31
Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. 54
19251084 2009
32
TLR9-activating DNA up-regulates ZAP70 via sustained PKB induction in IgM+ B cells. 54
19050243 2008
33
Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. 54
18768392 2008
34
The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL). 54
18499249 2008
35
P2X7 gene polymorphisms do not appear to be a susceptibility gene locus in sporadic cases of systemic lupus erythematosus. 54
18937793 2008
36
IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression. 54
18941194 2008
37
Detection of ZAP-70 in patients with chronic lymphocytic leukemia. 54
19145677 2008
38
Lipopolysaccharide activates NF-kappaB by TLR4-Bcl10-dependent and independent pathways in colonic epithelial cells. 54
18718996 2008
39
Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells. 54
18794139 2008
40
Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. 54
18521849 2008
41
Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation. 54
18474259 2008
42
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. 54
18497318 2008
43
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. 54
18314442 2008
44
The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia. 54
18702872 2008
45
DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. 54
18559621 2008
46
[In silico identification, molecular cloning and verification of a novel pig gene homologous to human BCL10 of innate immunity and its preliminary expression profiles in pigs]. 54
18550498 2008
47
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. 54
18467716 2008
48
Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. 54
18398743 2008
49
Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. 54
18252714 2008
50
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. 54
18079738 2008
Sources

Variations for Leukemia, Chronic Lymphocytic 2

About this section
Sources

Expression for Leukemia, Chronic Lymphocytic 2

About this section
Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic 2.
Sources

Pathways for Leukemia, Chronic Lymphocytic 2

About this section

Pathways related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.61 MS4A1 CD5 CD38
2
Interleukin-4 and 13 signaling 65
11.55 MCL1 FCER2 BCL2
3
NF-kappa B signaling pathway 36
11.45 ZAP70 BCL2 ATM
4
Integrated Cancer Pathway 1
11.14 BCL2 ATM
5
Photodynamic therapy-induced AP-1 survival signaling. 1
11.04 MCL1 BCL3 BCL2
6
Hematopoietic cell lineage 36
10.92 MS4A1 FCER2 CD5 CD38
7
Gemtuzumab ozogamicin Pathway, Pharmacokinetics/Pharmacodynamics 60
10.82 BCL2 ATM
8
TP53 Network 1
Show member pathways
 10.78 BCL2 ATM
10
Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex 1
10.47 MCL1 BCL2 ATM
Sources

GO Terms for Leukemia, Chronic Lymphocytic 2

About this section

Cellular components related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 MS4A1 IGHM FCER2 CD5

Biological processes related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.71 MCL1 CD38 BCL3 BCL2
2 thymus development GO:0048538 9.58 BCL2 ATM
3 neuron apoptotic process GO:0051402 9.57 BCL2 ATM
4 positive regulation of B cell proliferation GO:0030890 9.56 CD38 BCL2
5 regulation of apoptotic process GO:0042981 9.56 ATM BCL2 BCL3 MCL1
6 ovarian follicle development GO:0001541 9.55 BCL2 ATM
7 T cell differentiation GO:0030217 9.54 ZAP70 BCL2
8 B cell activation GO:0042113 9.52 ZAP70 MS4A1
9 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.51 MCL1 BCL2
10 B cell proliferation GO:0042100 9.49 MS4A1 BCL2
11 spleen development GO:0048536 9.48 BCL3 BCL2
12 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.46 MCL1 BCL2
13 negative regulation of intrinsic apoptotic signaling pathway GO:2001243 9.43 MCL1 BCL2
14 negative regulation of anoikis GO:2000811 9.37 MCL1 BCL2
15 response to cytokine GO:0034097 9.33 MCL1 CD38 BCL2
16 oocyte development GO:0048599 9.32 BCL2 ATM
17 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.13 MCL1 BCL2 ATM
18 B cell receptor signaling pathway GO:0050853 8.92 MS4A1 IGHM CD38 BCL2

Molecular functions related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 BH3 domain binding GO:0051434 8.62 MCL1 BCL2
Sources

Sources for Leukemia, Chronic Lymphocytic 2

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....